U.S. Navy to fund Vical’s H1N1 vaccine

Business of Biotech

The U.S. Navy has awarded a contract for $1.25 million to Vical Incorporated (Nasdaq:VICL) for large-scale cGMP vaccine manufacturing and related clinical and regulatory preparations, which are already underway, for a Phase 1 clinical trial of the company’s vaccine against A/H1N1 pandemic influenza. The trial will be conducted in collaboration with the U.S. Naval Medical Research Center. Vical was the first company to produce a vaccine against the A/H1N1 influenza virus after the initial reports of widespread outbreaks in Mexico, and the first to announce immunogenicity results from animal testing in two species.

Business of Biotech  |  Email This Post  |  Printer Friendly
Tags: ,

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>